Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | LATS1 | O95835 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30197784 | 1.00 | PDGFRB (1.00) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL26928536 | 0.73 | KDR (0.61) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL26928576 | 0.72 | KDR (0.69) | PDGFRBFGFR1KDRPDGFRAFLT1 | |
| SCHEMBL30373592 | 0.71 | MAP2K5 (0.75) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL29374889 | 0.71 | MAP2K5 (0.83) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL30197767 | 0.71 | MAP2K5 (0.83) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL31046829 | 0.71 | MAP2K5 (1.00) | PDGFRBMAP2K1FGFR1MAP2K5CDC7 | |
| SCHEMBL26928451 | 0.68 | KDR (0.70) | PDGFRBFGFR1MAP2K5MELKMAPK7 | |
| SCHEMBL26928496 | 0.67 | KDR (0.84) | PDGFRBFGFR1KDRPDGFRAFLT1 | |
| SCHEMBL29418239 | 0.66 | KDR (0.85) | PDGFRBMAP2K1FGFR1AURKARPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| EP-4598532-A1 | COMBINATION OF SUBSTITUTED 2,4 DIAMINO-QUINOLINE COMPOUNDS AND MEK INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCERS | Genfit (FR) | 2025-08-13 | — | — | EP | claimed |
| US-12383738-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2025-08-12 | — | — | US | claimed |
| EP-4577639-A1 | METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION | Trailhead Biosystems Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| US-20250179584-A1 | PRECISION THERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-06-05 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-20230027059-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2023-01-26 | — | — | US | claimed |
| US-20230029259-A1 | COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-01-26 | — | — | US | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022178244-A1 | COMBINATION OF RAF INHIBITOR AND MEK INHIBITOR | DAY ONE BIOPHARMACEUTICALS, INC. (US) | 2022-08-25 | — | — | WO | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2022125941-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH BRAF INHIBITORS AND/OR MEK INHIBITORS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| EP-4003332-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-01 | — | — | EP | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029259-A1 | COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS | XIAP, BIRC5, BIRC3 | PDGFRB 2880/4885MAP2K1 65/4885FGFR1 4562/4885 |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | MDM2, TP53, BRCA1 | PDGFRB 2264/4885MAP2K1 3674/4885FGFR1 473/4885 |
| US-20250179584-A1 | PRECISION THERAPY FOR THE TREATMENT OF CANCER | KRAS, NRAS, BRAF | PDGFRB 1114/4885MAP2K1 43/4885FGFR1 352/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | PDGFRB 2235/4885MAP2K1 40/4885FGFR1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.